- Home
- HUHU vs CUE Comparison
HUHU vs CUE Comparison
Compare HUHU & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUHU
- CUE
- Stock Information
- Founded
- HUHU 2015
- CUE 2014
- Country
- HUHU China
- CUE United States
- Employees
- HUHU N/A
- CUE N/A
- Industry
- HUHU
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- HUHU
- CUE Health Care
- Exchange
- HUHU NYSE
- CUE Nasdaq
- Market Cap
- HUHU 86.8M
- CUE 77.3M
- IPO Year
- HUHU 2024
- CUE 2018
- Fundamental
- Price
- HUHU $4.56
- CUE $1.21
- Analyst Decision
- HUHU
- CUE Strong Buy
- Analyst Count
- HUHU 0
- CUE 5
- Target Price
- HUHU N/A
- CUE $5.00
- AVG Volume (30 Days)
- HUHU 57.2K
- CUE 409.4K
- Earning Date
- HUHU 02-22-2025
- CUE 03-10-2025
- Dividend Yield
- HUHU N/A
- CUE N/A
- EPS Growth
- HUHU 13.14
- CUE N/A
- EPS
- HUHU 0.08
- CUE N/A
- Revenue
- HUHU $17,492,735.00
- CUE $9,532,000.00
- Revenue This Year
- HUHU N/A
- CUE $73.11
- Revenue Next Year
- HUHU N/A
- CUE $11.02
- P/E Ratio
- HUHU $55.65
- CUE N/A
- Revenue Growth
- HUHU 33.03
- CUE 149.53
- 52 Week Low
- HUHU $3.52
- CUE $0.45
- 52 Week High
- HUHU $9.89
- CUE $2.88
- Technical
- Relative Strength Index (RSI)
- HUHU N/A
- CUE 48.27
- Support Level
- HUHU N/A
- CUE $1.21
- Resistance Level
- HUHU N/A
- CUE $1.33
- Average True Range (ATR)
- HUHU 0.00
- CUE 0.19
- MACD
- HUHU 0.00
- CUE -0.01
- Stochastic Oscillator
- HUHU 0.00
- CUE 32.50
About HUHU HUHUTECH INTL GROUP INC
HUHUTECH International Group Inc specializes in providing factory facility management and monitoring systems, including high-purity gas, chemicals and liquid system and factory management and control systems for industrial clients, who are mainly semi-conductor manufacturers and electronics manufacturers in China. The products and services are widely used by semi-conductor manufacturers, LED and micro-electronics factories, as well as some pharmaceutical, food and beverage manufacturers.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.